Machine learning to forecast rituximab responses for paediatric immune thrombocytopenia: Forging a path towards personalized medical care
- 15 July 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (2) , 463-474
Abstract
Summary: Primary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by decreased platelet counts and increased bleeding risk. Although paediatric ITP often resolves spontaneously, some children do not respond to first‐line treatments, thus requiring rituximab as a second‐line therapy to reduce bleeding risks and corticosteroid exposure. Currently, there is no reliable method to predict the efficacy of rituximab. Our study aimed to develop a machine learning (ML) model to predict the initial response to rituximab in these patients. We analysed data from 156 paediatric ITP patients treated at Beijing Children's Hospital between 2020 and 2023 and identified 25 key predictive features. Among the four evaluated ML models, the multilayer perceptron model exhibited the highest predictive accuracy. SHapley Additive exPlanations analysis revealed that antinuclear antibody titre, thyroglobulin antibody, corticosteroid response and bleeding severity were significant positive predictors, while thyroid peroxidase antibody, CD3+ CD4+ IL‐17+ T cells and the duration of disease before rituximab treatment were negatively associated with treatment responses. This ML model could be used to predict rituximab responses in paediatric ITP, which is expected to optimize treatment strategies and improve patient outcomes.Keywords
Funding Information
- National Key Research and Development Program of China (2023YFC2706100)
- National Natural Science Foundation of China (62476274, 81970111)
This publication has 43 references indexed in Scilit:
- Machine learning models developed and internally validated for predicting chronicity in pediatric immune thrombocytopeniaJournal of Thrombosis and Haemostasis, 2023
- Primary and secondary immune thrombocytopenia (ITP): Time for a rethinkBlood Reviews, 2023
- Systemic lupus erythematosus-complicating immune thrombocytopenia: From pathogenesis to treatmentJournal of Autoimmunity, 2022
- Adapted guideline for the diagnosis and treatment of primary immune thrombocytopenia for Chinese children (2021)Pediatric Investigation, 2022
- Response to rituximab in children and adults with immune thrombocytopenia (ITP)Research and Practice in Thrombosis and Haemostasis, 2021
- CD4+ T cell phenotypes in the pathogenesis of immune thrombocytopeniaCellular Immunology, 2020
- The potential therapeutic benefit of resveratrol on Th17/Treg imbalance in immune thrombocytopenic purpuraInternational Immunopharmacology, 2019
- Foxp3 methylation status in children with primary immune thrombocytopeniaHuman Immunology, 2014
- Applied Logistic Regression2013
- Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopeniaPediatric Blood & Cancer, 2011